Thyroid Function and Low Free Triiodothyronine in Chinese Patients With Autoimmune Encephalitis.
autoimmune encephalitis
free triiodothyronine
low-T3 syndrome
prognosis
thyroid function
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
11
2021
accepted:
24
01
2022
entrez:
28
2
2022
pubmed:
1
3
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Low free triiodothyronine (FT3) is usually associated with worse functional outcome in critical illness; however, the information on thyroid dysfunction and autoimmune encephalitis (AE) is limited. This study aims to evaluate the clinical prognostic value of thyroid function and low-T3 syndrome in patients with multiple subtypes of AE. In this retrospective study, we identified the hospital records of 319 candidate patients with AE admitted between January 2016 and December 2020. We then extracted the clinical features and outcomes. Modified Rankin scale (mRS) scores were used to evaluate the patients' neurological function. The serum levels of FT3, free thyroxine (FT4), and thyroid-stimulating hormone (TSH) were measured upon admission. Normal thyroid stimulating hormone level with FT3 below the lower limit of the reference interval (2.63 nmol/L) was defined as low-T3 syndrome. A total of 237 AE cases remained after screening. Among these, 57.81% (137/237) were men and the average age at onset was 41 y (interquartile range, 12-61 y). We found that 83.54% (198/237) of the patients had a good prognosis, and 16.46% (39/237) had a poor prognosis. Abnormal thyroid function was observed in 30.80% of these patients, with a relatively greater prevalence in the group with a poor prognosis ( Abnormal thyroid function in AE is frequent, and serum FT3 levels in patients with poor prognosis are significantly lower than in those with good prognosis. Low-T3 syndrome could be a potential candidate for predicting the prognosis of AE following future research.
Sections du résumé
Background and Objectives
Low free triiodothyronine (FT3) is usually associated with worse functional outcome in critical illness; however, the information on thyroid dysfunction and autoimmune encephalitis (AE) is limited. This study aims to evaluate the clinical prognostic value of thyroid function and low-T3 syndrome in patients with multiple subtypes of AE.
Methods
In this retrospective study, we identified the hospital records of 319 candidate patients with AE admitted between January 2016 and December 2020. We then extracted the clinical features and outcomes. Modified Rankin scale (mRS) scores were used to evaluate the patients' neurological function. The serum levels of FT3, free thyroxine (FT4), and thyroid-stimulating hormone (TSH) were measured upon admission. Normal thyroid stimulating hormone level with FT3 below the lower limit of the reference interval (2.63 nmol/L) was defined as low-T3 syndrome.
Results
A total of 237 AE cases remained after screening. Among these, 57.81% (137/237) were men and the average age at onset was 41 y (interquartile range, 12-61 y). We found that 83.54% (198/237) of the patients had a good prognosis, and 16.46% (39/237) had a poor prognosis. Abnormal thyroid function was observed in 30.80% of these patients, with a relatively greater prevalence in the group with a poor prognosis (
Conclusions
Abnormal thyroid function in AE is frequent, and serum FT3 levels in patients with poor prognosis are significantly lower than in those with good prognosis. Low-T3 syndrome could be a potential candidate for predicting the prognosis of AE following future research.
Identifiants
pubmed: 35222399
doi: 10.3389/fimmu.2022.821746
pmc: PMC8866758
doi:
Substances chimiques
Triiodothyronine
06LU7C9H1V
Thyroxine
Q51BO43MG4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
821746Informations de copyright
Copyright © 2022 Qiao, Zhang, Zhang, Wang, Wang, Jiang, Wang and Liu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurochem Int. 2018 Feb;113:107-111
pubmed: 29203399
Neuroimmunomodulation. 2018;25(2):110-117
pubmed: 30157483
J Autoimmun. 2019 Jan;96:24-34
pubmed: 30595145
Int J Cancer. 2018 Aug 1;143(3):466-477
pubmed: 29457831
J Intensive Care Med. 2021 Mar;36(3):313-318
pubmed: 31774023
J Child Neurol. 2015 Oct;30(12):1582-5
pubmed: 25792426
Front Neurol. 2021 May 31;12:642078
pubmed: 34135845
J Clin Pharm Ther. 2020 Aug;45(4):759-766
pubmed: 32406070
Am J Geriatr Psychiatry. 2018 Dec;26(12):1222-1230
pubmed: 30236902
J Neurooncol. 2017 Jan;131(2):385-391
pubmed: 27830477
Br J Haematol. 2017 Apr;177(1):95-105
pubmed: 28146267
Brain Commun. 2021 Jan 05;3(2):fcaa233
pubmed: 34061124
Autoimmun Rev. 2019 Feb;18(2):155-163
pubmed: 30572142
Front Neurol. 2021 Sep 09;12:707046
pubmed: 34566852
Rev Assoc Med Bras (1992). 2020 Oct;66(10):1327
pubmed: 33174920
Am J Case Rep. 2021 May 17;22:e931104
pubmed: 33999913
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e926-e935
pubmed: 33141191
Expert Rev Neurother. 2018 May;18(5):443-451
pubmed: 29533109
J Neurol Sci. 2016 Jul 15;366:3-7
pubmed: 27288767
Front Neurol. 2021 Jan 15;11:620483
pubmed: 33519701
Best Pract Res Clin Endocrinol Metab. 2019 Dec;33(6):101364
pubmed: 31801687
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Curr Opin Neurol. 2021 Apr 1;34(2):166-171
pubmed: 33464762
Ther Clin Risk Manag. 2021 Aug 19;17:851-861
pubmed: 34434048
Front Immunol. 2021 Sep 08;12:725950
pubmed: 34566983
Neuropsychiatr Dis Treat. 2021 Jan 25;17:203-212
pubmed: 33531809
Expert Rev Neurother. 2015 Mar;15(3):315-26
pubmed: 25673072